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Abstract
The article presents the case of a 59-year-old patient hospitalized due to myocardial infarction with ST-segment eleva-
tion, who developed a thrombus in the apex of the left ventricle in the early post-infarction period.
Key words: myocardial infarction, left ventricular thrombus, vitamin K antagonists
Folia Cardiologica 2021; 16, 2: 148–150
Introduction
The presence of thrombus in the left ventricle of the heart 
is one of the complications of acute coronary syndrome, 
associated with an increased risk of ischaemic stroke or 
systemic embolism [1]. The incidence of thrombus in car-
diac cavities as a complication of myocardial infarction is 
not high, and it is estimated that it occurs in less than 1% 
patients [2[. Factors which significantly increase the risk 
of thrombus formation include: myocardial infarction of 
the anterior wall, left ventricular ejection fraction < 35%, 
dyskinesia of the apex or left ventricular aneurysm [3]. Tre-
atment of patients with left ventricular thrombus consists in 
administering a vitamin K antagonist (VKA) for 3–6 months 
[4]. We present a clinical case report of a 59-year-old man 
hospitalized due to myocardial infarction complicated by 
a thrombus in the left ventricular apex.
Case study
A 59-year-old man was admitted to the cardiac intensive 
care unit due to acute coronary syndrome with ST-segment 
elevation (STEMI, ST-elevation myocardial infarction). 
Electrocardiography performed on admission revealed 
ST-segment elevation in the form of Pardee’s wave in leads 
V1–V6 (Figure 1). Laboratory tests revealed hypoglycaemia 
218 mg/dL (reference value 65–100 mg/dL), elevated 
concentration of myocardial necrosis markers: creatine 
kinase-myocardial bound (CK-MB) — 54 U/L (reference 
value 0–39 U/L), creatine phosphokinase (CPK) — 706 U/L 
(reference value 60–390 U/L) and troponin T — 453,1 ng/L 
(reference value 0.0–14.1 ng/L). The patient had a histo-
ry of cardiovascular risk factors: long-term nicotine use 
(30 pack-years), type 2 diabetes and hypercholesterolemia 
[high-density lipoproteins (HDL) — 31 mg/dL, low-density li-
poproteins (LDL) — 118 mg/dL, triglycerides — 119 mg/dL). 
The patient had not been receiving chronic treatment for 
his cardiovascular conditions and was managing diabetes 
with diet.
Transthoracic echocardiograph performed on admis-
sion revealed akinesis of the apex and the central and 
apical segments of the adjacent walls. Left ventricular 
ejection fraction was at 25%. Coronary angiography reve-
aled a critical 90% stenosis in the proximal segment of the 
anterior descending branch of the left coronary artery. At 
the same time, percutaneous coronary intervention (PCI) 
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Discussion
VKAs have been used to prevent and treat thromboembolic 
complications for over 50 years. Currently, they are increa-
singly often replaced with novel non-vitamin K antagonist 
anticoagulants (NOAC). NOACs are at least as effective 
VKAs and show a higher safety profile. NOACs are preferred 
for the treatment of patients with such diseases as atrial 
fibrillation and venous thromboembolism [5, 6]. However, 
VKA treatment remains the first-line therapy in patients 
with mechanical heart valves, atrial fibrillation with mode-
rate or severe mitral stenosis as well as patients with left 
ventricular thrombus [4, 7].
Left ventricular thrombus formation may be a complica-
tion of myocardial infarctions, particularly those involving 
with drug-eluting stent (DES) implantation was performed 
without complications.
The evolution of the myocardial infarction was observed 
in follow-up (ECG) conducted during the hospitalization. It 
revealed a thrombus in the lumen of the left ventricular 
apex (Figure 2), left ventricular ejection fraction was at 
34%. The patient was discharged from the hospital 7 days 
after the infarction with the following recommendations 
regarding further treatment: acetylsalicylic acid 75 mg, 
clopidogrel 75 mg, warfarin 5 mg [controlling the interna-
tional normalized ratio (INR), which should be at 2–2.5], 
bisoprolol 5 mg, ramipril 5 mg, atorvasterol 80 mg, eplere-
none 50 mg, metformin 1,000 mg and empagliflozin 10 mg. 
The patient was instructed to report to follow-up echocar-
diography after 3 months.
Figure 1. Electrocardiogram — sinus rhythm, regular, frequency of 88/min, normogram, ST-segment elevation in leads V1–V6
Figure 2A, B. Transthoracic echocardiography: thrombus in the left ventricular apex in four-chamber apical view and three-chamber apical view
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the anterior wall, the apex and apical segments [8]. Other 
factors favouring the thrombus formation include left ven-
tricular ejection fraction < 35% and apical dyskinesis or 
left ventricular aneurysm [3]. Due to the fact that throm-
bus may form after approximately 24 hours from the oc-
currence of acute coronary syndrome, it is important to 
perform follow-up echocardiography in days following the 
infarction. Two-dimensional transthoracic echocardiogra-
phy is highly specific (85–95%) and sensitive (95%) in the 
detection of left ventricular thrombi. Thrombi present as 
separate masses with well-defined margins that are distin-
ct from the endocardium. It can be visualized during both 
systole and diastole. According to studies, 90% of throm-
bi form within 2 weeks after infarction. In some patients, 
thrombi formation is observed after discharge from hospi-
tal as a result of deteriorating systolic function of the left 
ventricle [8]. Presence of thrombus in the left ventricle is 
associated with an increased risk of systemic embolism, 
for example ischaemic brain stroke. With anticoagulation 
treatment, the incidence of thromboembolic events can be 
significantly reduced [8].
In the patient in question, thrombus was found on the 
third day following the infarction. The electrocardiographic 
image revealed infarction of the anterior and lateral wall, 
which is associated with poor prognosis due to a higher 
incidence of thrombus formation in the left ventricle [9]. 
Due to the fact that VKA therapy is the first-line treatment 
in such cases, anticoagulant therapy with warfarin was im-
plemented. Clinical experience with the use of NOACs in pa-
tients with post-infarction thrombus in the left ventricle is 
limited, although recently published data shed new light on 
the use of NOAC in this group of patients. An observational 
study involving 2,328 patients after myocardial infarction 
undergoing percutaneous coronary revascularization sho-
wed that thrombus in the left ventricle was observed in 
101 patients. VKAs were given to 59.5% of them, while 
40.6% received NOACs. Thrombus involution was faster in 
patients who received NOACs. In addition, the process was 
observed in a greater percentage of patients than in the 
group of individuals treated with VKAs. In addition, fewer 
bleeding complications were observed in patients treated 
with NOACs [10]. Further studies confirming the effective-
ness and safety of NAOC therapy in patients with left ven-
tricular apical thrombus are needed.
Summary
The treatment applied in the presented case consisted 
in a combination of two antiplatelet drugs and a vitamin 
K antagonist. There is numerous scientific evidence 
proving that combining antiplatelet drugs with NOACs in 
atrial fibrillation patients and patients after myocardial 
infarction/coronary revascularization is safe and effective. 
There are also reports indicating that such a combination 
can be used in patients in whom anticoagulant treatment 
should be introduced due to a left ventricular thrombus. It 
seems that this will be an increasingly common solution.
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